Pharmaceutical and biotechnology companies buy more drug discovery than anyone else. In 2025 they accounted for 68% of global revenue, worth USD 50.66 billion. Academic institutes and other research groups make up the remainder of demand. What these buyers purchase is research capacity: services and platforms for identifying, validating and optimizing therapeutic candidates before formal preclinical testing begins. That spans target identification, hit-to-lead chemistry, biological screening and early candidate characterization. Large drug makers run internal pipelines and still contract out chemistry, biology and informatics work. Smaller biotechnology firms and academic groups lean on outside providers for specialized screening and validation they cannot staff themselves.
Contrive Datum Insights has published "Drug Discovery Market Size, Share & Industry Analysis" with a forecast window of 2026 to 2034. The study sizes the global market at USD 74.5 billion in 2025 and projects USD 81.5 billion in 2026, rising to USD 164.78 billion by 2034. That is a compound annual growth rate of 9.2% across the forecast period.
Where spending concentrates, and where it is heading
By service type, Chemistry Services took 55% of 2025 revenue (USD 40.98 billion), but Biology Services grows faster at 10.51%. The same split shows up by molecule class. Small Molecules led with 58% of revenue and USD 43.21 billion, while Large Molecules (Biopharmaceuticals) expands at 10.84%, the quicker of the two.
Workflow tells a similar story. Lead Identification & Candidate Optimization is the biggest line, with 32% of 2025 revenue at USD 23.84 billion, yet it grows at 8.82%, a little under the market as a whole. Target Identification & Screening starts smaller and moves faster. It grows at 10.76%, lifting its share of revenue from 22% to 25% and its value from USD 16.39 billion to USD 41.2 billion by 2034. By therapeutic area, Oncology led in 2025 with 26% of revenue (USD 19.37 billion), and Immunomodulation posts the fastest growth at 10.5%.
Geography is more concentrated at the top. North America held 42% of 2025 revenue at USD 31.29 billion and reaches USD 62.62 billion by 2034. The United States alone is the largest country market, at USD 26.6 billion in 2025 and 35.7% of the global total. Asia Pacific is the region gaining ground, moving from 27% of revenue in 2025 to 33% in 2034 as its value climbs from USD 20.12 billion to USD 54.38 billion. Middle East and Africa stays the smallest region at 3% in both years.
The study names rising biologics and cell and gene therapy pipelines as the largest single contributor to growth, and it rates the impact high. Those pipelines need specialized discovery services, and the workflow and molecule lines tied to them are the ones growing fastest.
The outlook carries a range. If biologics pipeline growth and Asia Pacific outsourcing capacity both outrun the base case, 2034 revenue reaches USD 181.26 billion. If pharmaceutical R&D budgets are trimmed and biologics programs advance more slowly, it stops at USD 148.3 billion. The base case sits between them at USD 164.78 billion.
The report covers five segmentation axes (workflow, therapeutics area, drug type, type and end-user), all five regions with country-level detail, the competitive landscape and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.